Clinical Advances of 225Ac-targeted Antibody & Small Molecule-based Agents & Revealing Preclinical Insights from Immune Checkpoint Combination Approaches
Time: 11:45 am
day: Day One LSC AM
Details:
- Outlining why 225Ac is an attractive radioisotope for targeted therapy
- Exploring clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (a phase 2/3 study)
- Revealing rational drug combinations for targeted alpha therapeutics
